US Patient Receives Novel Cancer Drug in China
An American patient with advanced lung cancer has been stabilized using a novel immunotherapy treatment currently available only in China. The patient was treated with ivonescimab at Shanghai's Jiahui International Cancer Center. The case highlights the globalization of cutting-edge medical treatments and China's growing role in developing new cancer therapies.
Ivonescimab, the drug administered, is a potential first-in-class bispecific antibody developed by Chinese biotech Akeso Inc. It uniquely combines the functions of two proven cancer-fighting mechanisms: blocking the PD-1 protein to unleash an immune response against cancer cells, and inhibiting VEGF to cut off the tumor's blood supply. This dual-action is designed to be more effective than administering two separate drugs that perform these functions. The treatment represents a significant milestone in the globalization of pharmaceuticals, a space where Chinese firms are increasingly becoming innovators rather than imitators. In a landmark deal worth up to $5 billion, U.S.-based Summit Therapeutics acquired the rights to develop and commercialize ivonescimab in the U.S., Canada, Europe, and Japan. Akeso retains the rights for China and other regions. China's pharmaceutical industry has seen a dramatic rise in prominence. In the first half of 2023, 46% of new drug molecules that entered human trials originated from Chinese companies, a significant increase from 17% a decade prior. This surge is particularly notable in oncology, where Chinese firms are responsible for approximately 60% of the global development of bispecific antibodies like ivonescimab. Clinical trials for ivonescimab have shown promising results. In a Phase III study in China, the drug demonstrated a statistically significant improvement in progression-free survival for patients with a specific type of non-small cell lung cancer compared to the standard of care. These strong results from Chinese patient trials are now being tested in Phase III trials in the United States to support a potential FDA approval. The Jiahui International Cancer Center in Shanghai, where the patient was treated, is a key player in this cross-border healthcare ecosystem. It has a strategic collaboration with Massachusetts General Hospital, a teaching hospital of Harvard Medical School, to provide care that aligns with international standards. This partnership facilitates access to cutting-edge treatments developed in China for a global patient base. This case also brings to light the significant cost disparities in cancer care. While a specific price for ivonescimab has not been set in the U.S., other Chinese-developed cancer drugs have been priced substantially lower in China than in the U.S. market. For instance, the cancer drug toripalimab costs over 30 times more in the U.S. than in China, though it is still priced 20% below its key American competitor. This trend suggests that as more Chinese-developed drugs enter the U.S. market, they could introduce new pricing dynamics.
